Skip to contentS
Sunshine Biopharma Inc.
S
SBFMSunshine Biopharma Inc. Q1 2025 · 10-Q
Revenue$8.90M$8.90M+18.0% vs Q1 2024 Net Income-$1.18M-$1.18MN/M vs Q1 2024 EPS Diluted-$0.44-$0.44N/M vs Q1 2024 Gross Profit$2,730,426+16.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sunshine Biopharma Inc. · CIK 1402328 · Engraved from SEC EDGAR
Operating Cash Flow-$1,695,002N/M Free Cash Flowderived-$1,702,492N/M Margins · derivedGross margin30.7%−0.5 pt vs Q1 2024
Operating margin-14.6%+3.4 pt vs Q1 2024
Net margin-13.3%+3.8 pt vs Q1 2024
ended Mar 31, 2025 · filed May 15, 2025 · 45 d after period end